Matinas Biopharma (MTNB) Competitors $0.59 0.00 (-0.34%) As of 03:11 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock MTNB vs. AFMD, RLYB, RLMD, PHXM, IXHL, GOVX, NXTC, DWTX, HOTH, and TRIBShould you be buying Matinas Biopharma stock or one of its competitors? The main competitors of Matinas Biopharma include Affimed (AFMD), Rallybio (RLYB), Relmada Therapeutics (RLMD), PHAXIAM Therapeutics (PHXM), Incannex Healthcare (IXHL), GeoVax Labs (GOVX), NextCure (NXTC), Dogwood Therapeutics (DWTX), Hoth Therapeutics (HOTH), and Trinity Biotech (TRIB). These companies are all part of the "pharmaceutical products" industry. Matinas Biopharma vs. Affimed Rallybio Relmada Therapeutics PHAXIAM Therapeutics Incannex Healthcare GeoVax Labs NextCure Dogwood Therapeutics Hoth Therapeutics Trinity Biotech Matinas Biopharma (NYSE:MTNB) and Affimed (NASDAQ:AFMD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, community ranking, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership. Does the MarketBeat Community prefer MTNB or AFMD? Affimed received 439 more outperform votes than Matinas Biopharma when rated by MarketBeat users. CompanyUnderperformOutperformMatinas BiopharmaN/AN/AAffimedOutperform Votes43969.79% Underperform Votes19030.21% Do analysts rate MTNB or AFMD? Affimed has a consensus price target of $13.50, suggesting a potential upside of 1,116.22%. Given Affimed's stronger consensus rating and higher probable upside, analysts plainly believe Affimed is more favorable than Matinas Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Matinas Biopharma 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Affimed 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Is MTNB or AFMD more profitable? Matinas Biopharma has a net margin of 0.00% compared to Affimed's net margin of -7,836.26%. Matinas Biopharma's return on equity of -123.06% beat Affimed's return on equity.Company Net Margins Return on Equity Return on Assets Matinas BiopharmaN/A -123.06% -94.28% Affimed -7,836.26%-193.84%-107.24% Do institutionals & insiders believe in MTNB or AFMD? 11.8% of Matinas Biopharma shares are owned by institutional investors. Comparatively, 30.8% of Affimed shares are owned by institutional investors. 6.0% of Matinas Biopharma shares are owned by company insiders. Comparatively, 3.8% of Affimed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has higher earnings and valuation, MTNB or AFMD? Matinas Biopharma has higher revenue and earnings than Affimed. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMatinas Biopharma$1.10M2.72-$22.94M-$5.03-0.12Affimed$877K20.38-$114.66MN/AN/A Which has more risk & volatility, MTNB or AFMD? Matinas Biopharma has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Comparatively, Affimed has a beta of 2.28, indicating that its share price is 128% more volatile than the S&P 500. Does the media favor MTNB or AFMD? In the previous week, Affimed had 4 more articles in the media than Matinas Biopharma. MarketBeat recorded 5 mentions for Affimed and 1 mentions for Matinas Biopharma. Matinas Biopharma's average media sentiment score of 0.59 beat Affimed's score of 0.55 indicating that Matinas Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Matinas Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Affimed 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAffimed beats Matinas Biopharma on 8 of the 15 factors compared between the two stocks. Get Matinas Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTNB vs. The Competition Export to ExcelMetricMatinas BiopharmaPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$3.00M$6.74B$5.50B$18.97BDividend YieldN/A3.05%5.11%4.02%P/E Ratio-0.127.3622.6332.98Price / Sales2.72242.40398.0928.04Price / CashN/A65.8538.1817.52Price / Book0.136.506.724.49Net Income-$22.94M$143.41M$3.22B$1.02B7 Day Performance-1.01%2.04%1.58%0.94%1 Month Performance6.90%6.96%4.09%-2.42%1 Year PerformanceN/A-2.51%16.05%4.78% Matinas Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTNBMatinas BiopharmaN/A$0.59-0.3%N/A+218.3%$3.00M$1.10M-0.1230AFMDAffimed3.5165 of 5 stars$0.70-4.0%$13.50+1,818.2%-81.4%$11.33M$877,000.000.00200RLYBRallybio2.3249 of 5 stars$0.27+6.0%$10.00+3,672.2%-83.3%$11.03M$636,000.00-0.1740Upcoming EarningsGap UpRLMDRelmada Therapeutics4.3497 of 5 stars$0.32+11.5%$4.25+1,215.8%-91.1%$10.72MN/A-0.1110Upcoming EarningsPHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049IXHLIncannex Healthcare0.6312 of 5 stars$0.59-1.7%N/A-94.9%$10.54M$98,000.00-0.423Short Interest ↑GOVXGeoVax Labs2.7814 of 5 stars$0.76-8.4%$12.90+1,597.1%-27.9%$10.52M$3.95M-0.1310NXTCNextCure4.6485 of 5 stars$0.37+2.2%$3.50+848.5%-61.5%$10.35MN/A-0.1890Short Interest ↓Positive NewsGap DownHigh Trading VolumeDWTXDogwood Therapeutics2.2406 of 5 stars$5.37+25.8%N/AN/A$10.26MN/A-0.825Upcoming EarningsPositive NewsHigh Trading VolumeHOTHHoth Therapeutics3.1687 of 5 stars$0.77-2.0%$4.00+418.5%-26.3%$10.16MN/A-0.584Short Interest ↓Gap DownTRIBTrinity Biotech1.6645 of 5 stars$0.56+1.5%N/A-57.0%$10.07M$59.13M-0.25480Analyst ForecastShort Interest ↓Positive NewsGap Up Related Companies and Tools Related Companies AFMD Alternatives RLYB Alternatives RLMD Alternatives PHXM Alternatives IXHL Alternatives GOVX Alternatives NXTC Alternatives DWTX Alternatives HOTH Alternatives TRIB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:MTNB) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Matinas Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Matinas Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MTNB Stock Free MTNB Stock Alerts